• Labcorp Holdings recently announced that Megan D. Bailey will resign as Executive Vice President and President, Central Laboratories and International on September 4, 2026, with Brian J. Caveney, M.D., expanding his leadership role over Biopharma Laboratory Services and related businesses.
• Earlier this month, Labcorp also began offering Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay nationwide, broadening access to companion diagnostic testing that can help guide targeted treatment decisions for prostate cancer patients.
• We’ll now examine how Labcorp’s nationwide rollout of the PTEN companion diagnostic could influence its oncology-focused investment narrative.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Labcorp Holdings Investment Narrative Recap

To own Labcorp, you need to believe it can keep growing as a scaled, innovation-focused lab partner while managing reimbursement, regulation and competition. The nationwide rollout of Roche’s PTEN companion diagnostic and the leadership change in Biopharma Laboratory Services both support Labcorp’s oncology and biopharma positioning, but do not materially alter the most important near term catalyst, which remains execution on higher value test adoption, or the key risk from potential reimbursement pressure, including PAMA.

The launch of the VENTANA PTEN (SP218) RxDx Assay looks most relevant here, because it plugs directly into Labcorp’s precision oncology push and broader genomic and companion diagnostic portfolio. Its ability to bundle PTEN testing with existing oncology assays may help Labcorp deepen relationships with oncologists and biopharma partners, which ties into the broader catalyst of growing higher complexity testing, even as the company remains exposed to regulatory and pricing risks across core diagnostics.

But investors should also be aware that if reimbursement pressure, including possible PAMA changes, bites harder than expected...

Labcorp Holdings’ narrative projects $16.6 billion in revenue and $1.4 billion in earnings by 2029.

Uncover how Labcorp Holdings' forecasts yield a $337.75 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span US$260 to US$337.75, underscoring how differently individual investors view Labcorp. When you weigh those views against ongoing reimbursement and regulatory risks, it pays to compare several perspectives on the company’s future performance.

Explore 3 other fair value estimates on Labcorp Holdings - why the stock might be worth as much as $337.75!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Labcorp Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Labcorp Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Labcorp Holdings' overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Find 53 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.